Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart C Jacobs

Showing results (11-20 of 222) with videos related to

Pageof 23
Sort By:
Journal of the Peripheral Nervous System : JPNS|June 24, 2011
Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDPPieter A van Doorn, Krista Kuitwaard, Bart C Jacobs
Expert Opinion on Emerging Drugs|March 1, 2011
Emerging drugs for Guillain-Barré syndromeChrista Walgaard, Bart C Jacobs, Pieter A van Doorn
The Lancet. Neurology|October 14, 2008
Clinical features, pathogenesis, and treatment of Guillain-Barré syndromePieter A van Doorn, Liselotte Ruts, Bart C Jacobs
Trends in Immunology|April 23, 2004
The Guillain-Barré syndrome: a true case of molecular mimicryC Wim Ang, Bart C Jacobs, Jon D Laman
Journal of Neurology, Neurosurgery, and Psychiatry|November 13, 2016
Treatment dilemmas in Guillain-Barré syndromeChristine Verboon, Pieter A van Doorn, Bart C Jacobs
Current Opinion in Neurology|August 4, 2018
Advances in management of Guillain-Barré syndromeAlex Y Doets, Bart C Jacobs, Pieter A van Doorn
Lancet (London, England)|January 26, 2017
Guillain-Barré syndrome: surveillance and cost of treatment strategies - Authors' replyHugh J Willison, Bart C Jacobs, Pieter A van Doorn
Lancet (London, England)|March 8, 2016
Guillain-Barré syndromeHugh J Willison, Bart C Jacobs, Pieter A van Doorn
Annals of Clinical and Translational Neurology|September 26, 2018
Reply to: Comment on: Zika virus and Guillain-Barré syndrome in BangladeshCorine H GeurtsvanKessel, Zhahirul Islam, Bart C Jacobs, et al.
Trends in Immunology|March 8, 2022
Guillain-Barré syndrome: expanding the concept of molecular mimicryJon D Laman, Ruth Huizinga, Geert-Jan Boons, et al.
Pageof 23

Showing results (11-20 of 222) with videos related to

Sort By:
Pageof 23
Journal of the Peripheral Nervous System : JPNS|June 24, 2011
Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDPPieter A van Doorn, Krista Kuitwaard, Bart C Jacobs
Expert Opinion on Emerging Drugs|March 1, 2011
Emerging drugs for Guillain-Barré syndromeChrista Walgaard, Bart C Jacobs, Pieter A van Doorn
The Lancet. Neurology|October 14, 2008
Clinical features, pathogenesis, and treatment of Guillain-Barré syndromePieter A van Doorn, Liselotte Ruts, Bart C Jacobs
Trends in Immunology|April 23, 2004
The Guillain-Barré syndrome: a true case of molecular mimicryC Wim Ang, Bart C Jacobs, Jon D Laman
Journal of Neurology, Neurosurgery, and Psychiatry|November 13, 2016
Treatment dilemmas in Guillain-Barré syndromeChristine Verboon, Pieter A van Doorn, Bart C Jacobs
Current Opinion in Neurology|August 4, 2018
Advances in management of Guillain-Barré syndromeAlex Y Doets, Bart C Jacobs, Pieter A van Doorn
Lancet (London, England)|January 26, 2017
Guillain-Barré syndrome: surveillance and cost of treatment strategies - Authors' replyHugh J Willison, Bart C Jacobs, Pieter A van Doorn
Lancet (London, England)|March 8, 2016
Guillain-Barré syndromeHugh J Willison, Bart C Jacobs, Pieter A van Doorn
Annals of Clinical and Translational Neurology|September 26, 2018
Reply to: Comment on: Zika virus and Guillain-Barré syndrome in BangladeshCorine H GeurtsvanKessel, Zhahirul Islam, Bart C Jacobs, et al.
Trends in Immunology|March 8, 2022
Guillain-Barré syndrome: expanding the concept of molecular mimicryJon D Laman, Ruth Huizinga, Geert-Jan Boons, et al.
Pageof 23